个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
刘元波，主任医师、医学博士、教授，博士研究生导师。现任首都医科大学附属北京天坛医院血液内科主任。
研究方向:
1. 血液肿瘤诊治；
2. 原发性中枢神经系统淋巴瘤化疗及生物靶向治疗；
3. 脑肿瘤精准诊疗。
任职：
1. 首都医科大学血液病学系副主任；
2. 北京医师学会血液学分会委员；
3. 北京医师协会血液内科专科医师分会理事；
4. 北京癌症防治学会恶性血液病专业委员会委员
5. 北京围手术期医学研究会血液分会常务委员；
6. 中国抗癌协会血液肿瘤委员会中枢神经系统淋巴瘤工作组组长；
7. 中国研究型医院学会血液病精准诊疗专业委员会常务委员；
8. 中国医药教育协会造血干细胞移植及细胞治疗专业委员会委员；
9. 中国医药教育协会血液学专业委员会委员；
10. 中国医药教育协会淋巴瘤分会委员；
11. 中国医药教育协会淋巴疾病专业委员会委员；
12. 亚太医学生物免疫学会常务委员；
13. 亚太医学生物免疫学会血液学分会副主委；
14. 北京海聚工程人才、北京市特聘专家；
2020-2023在研:首都卫生发展科研专项项目:原发性中枢神经系统淋巴瘤诱导缓解后大剂量化疗与全脑放疗的疗效比较:一项前瞻性、随机、盲法评价结局临床试验
2020-2023主持在研:首都卫生发展科研专项项目,原发性中枢神经系统淋巴瘤诱导缓解后大剂量化疗与全脑放 疗的疗效比较:一项前瞻性、随机、盲法评价结局临床试验
2022年主持横向课题:治疗脑血管病的骨髓间充质干细胞质量研究;
参与项目:基于PCT药筛技术的复发高级别胶质瘤精准治疗研究;国家自然科学基金委员会批准开展的“神经再生胶原支架移植治疗脊髓损伤临床转化研究”课题研究
1.Sun X, Wu Y, Xing R, et al. Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China [Original Research]. 2022 2022-February-23;12. English. doi:10.3389/fonc.2022.792274.
●2.Zhang X, Wu Y, Sun X, et al. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis. BMC cancer. 2022 Feb 20;22(1):190. eng. Epub 2022/02/22. doi:10.1186/s12885-022-09275-z. Cited in: Pubmed; PMID 35184749.
●3.Liu J, Guo J, Sun X, et al. Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis. Frontiers in oncology. 2021;11:799721. eng. Epub 2022/02/01. doi:10.3389/fonc.2021.799721. Cited in: Pubmed; PMID 35096600.
●4.Wu Y, Sun X, Bai X, et al. Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study. Chinese neurosurgical journal. 2021 Apr 2;7(1):20. eng. Epub 2021/04/03. doi:10.1186/s41016-021-00238-0. Cited in: Pubmed; PMID 33795020.
●5.Lv L, Liu Y. Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma. Frontiers in oncology. 2021;11:658234. eng. Epub 2021/04/06. doi:10.3389/fonc.2021.658234. Cited in: Pubmed; PMID 33816315.
●6.Lv L, Sun X, Wu Y, et al. Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis. Frontiers in oncology. 2021;11:707285. eng. Epub 2021/07/20. doi:10.3389/fonc.2021.707285. Cited in: Pubmed; PMID 34277452.
●7.Fu F, Sun X, Li Y, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict chemotherapeutic responses and survival in primary central-nervous-system lymphoma. European radiology. 2021 Apr;31(4):1863-1871. eng. Epub 2020/10/01. doi:10.1007/s00330-020-07296-5. Cited in: Pubmed; PMID 32997181.
●8.Zhang X, Liu Y. Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects. CNS & neurological disorders drug targets. 2020;19(3):165-173. eng. Epub 2020/05/18. doi:10.2174/1871527319666200517112252. Cited in: Pubmed; PMID 32416683.
●9.Shen N, Wang Y, Sun X, et al. Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors. Brain and behavior. 2020 Aug;10(8):e01718. eng. Epub 2020/06/14. doi:10.1002/brb3.1718. Cited in: Pubmed; PMID 32533646.
●10.Yang X, Wang Y, Sun X, et al. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma. World neurosurgery. 2020 Feb;134:e1077-e1084. eng. Epub 2019/11/30. doi:10.1016/j.wneu.2019.11.100. Cited in: Pubmed; PMID 31778838.
●11.Wu Y, Wang Y, Sun X, et al. Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population. BMC neurology. 2019 Nov 4;19(1):268. eng. Epub 2019/11/07. doi:10.1186/s12883-019-1511-3. Cited in: Pubmed; PMID 31684888.
●12.Wu Y, Sun X, Liu J, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature. Chinese neurosurgical journal. 2018;4:1. eng. Epub 2018/01/08. doi:10.1186/s41016-017-0106-3. Cited in: Pubmed; PMID 32922862.
●13.Sun X, Liu J, Wang Y, et al. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Oncotarget. 2017 Jul 25;8(30):49156-49164. eng. Epub 2017/05/04. doi:10.18632/oncotarget.17101. Cited in: Pubmed; PMID 28467782.
●14..Yang XL, Liu YB. Advances in Pathobiology of Primary Central Nervous System Lymphoma. Chinese medical journal. 2017 Aug 20;130(16):1973-1979. eng. Epub 2017/08/05. doi:10.4103/0366-6999.211879. Cited in: Pubmed; PMID 28776551.
●15.Liu J, Wang Y, Liu Y, et al. Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases. Oncology letters. 2017 Nov;14(5):5505-5512. eng. Epub 2017/11/09. doi:10.3892/ol.2017.6893. Cited in: Pubmed; PMID 29113178.
●16.Liu J, Wang Y, Sun X, et al. Lesions of the central nervous system in leukemia: Pathological and magnetic resonance imaging features at presentation in 14 patients. Oncology letters. 2017 Dec;14(6):8162-8170. eng. Epub 2018/01/19. doi:10.3892/ol.2017.7192. Cited in: Pubmed; PMID 29344259.
●17.Liu J, Sun XF, Qian J, et al. Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Molecular and clinical oncology. 2015 Jul;3(4):949-953. eng. Epub 2015/07/15.doi:10.3892/mco.2015.566. Cited in: Pubmed; PMID 26171213.
●18.郭佳媛,武雨辰,刘元波.继发性中枢神经系统淋巴瘤预防与诊治研究进展[J]. 中华肿瘤防治杂志,2021(12). DOI:10.16073/j.cnki.cjcpt.2021.12.02.
19.陈悦丹,孙雪飞,王亚明,等.剂量调整R-MAD方案治疗老年原发性中枢神经系统淋巴瘤疗效观察[J].中华肿瘤防治杂志,2021,28(20):1573-1577. DOI:10.16073/j.cnki.cjcpt.2021.20.10.
20.陈悦丹,刘焕光,孙雪飞,等.伊布替尼联合化疗治疗复发难治原发性中枢神经系统淋巴瘤的初步探讨[J].中华神经外科杂志,2020,36(10):1047-1051. DOI:10.3760/cma.j.cn112050-20200513-00287.
21.丁慧,陶荣杰,刘元波.原发性中枢神经系统淋巴瘤治疗进展[J].中华肿瘤防治杂志,2018,25(5):375-380.
22.杨雪良,刘元波.原发性中枢神经系统淋巴瘤的免疫化学治疗进展[J].临床内科杂志,2018,35(5):297-300. DOI:10.3969/j.issn.1001-9057.2018.05.002.
23.孙雪飞,刘静,孙胜军,et al. 利妥昔单抗联合化疗方案治疗原发性中枢神经系统淋巴瘤的疗效. 2016;(32):388-392.
24.李扬,刘福生,刘元波,等.原发性中枢神经系统淋巴瘤的诊断与治疗[J].中华血液学杂志,2014,35(8):771-773. DOI:10.3760/cma.j.issn.0253-2727.2014.08.027.
25.刘静.原发性中枢神经系统淋巴瘤分子病理机制的研究进展[J].国际输血及血液学杂志,2015(4). DOI:10.3760/cma.j.issn.1673-419X.2015.04.011.
文件上传中...
